Researching and developing novel medicines targeting cancer drug resistance is at the core of what we do at Scandion Oncology, in our aim to transform the future of cancer therapeutics.
Our efforts are driven by our dedicated pre-clinical and clinical teams together with collaborators, advisors and key opinion leaders, with the focus of solving the unmet medical need for patients with drug resistant cancers.